#CSTL hashtag - Bluesky

#CSTL Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

www.stocktitan.net/news/CSTL/expert-melanom...

0 0 0 0

Market Wire News

@marketwirenews.com

4 months ago

Breaking News: ( NASDAQ: #CSTL ) Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity Castle Biosciences (Nasdaq: CSTL) reported new data showing its DecisionDx-Melanoma test improves sentinel lymph node biopsy (SLNB) decision-making and recurrence risk prediction in cutaneous melanoma. Two oral presentations will occur at ECDO on Nov 17–18, 2025.The i31-SLNB algorithm outperformed the MIA nomogram (AUC=0.74 vs. 0.61; p=0.001), identifying a 2.6% actual SLN positivity rate for patients predicted 5.8% by MIA. In a multicenter study of 810 SLN-negative patients, the 31-GEP independently predicted poorer five-year outcomes (Class 2B vs others; p<0.001) and improved prognostic accuracy when added to AJCC staging (ANOVA χ²=7.75, p=0.02).

#CSTL New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

www.stocktitan.net/news/CSTL/new-data-confi...

0 0 0 0

Market Wire News

@marketwirenews.com

4 months ago

NEWS: ( NASDAQ: #CSTL ) Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Trade Alerts, Tuesday November 4, 2025 – Crystal Equity Research

Small-cap stocks in new uptrend, average directional index, Tue Nov 4th - #MRT #APUS #TRST #MNOV #JRVR #IHRT #GLDD #CSTL #SMHI #AMTD - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Castle Biosciences Reports Third Quarter 2025 Results Castle Biosciences (Nasdaq: CSTL) reported Q3 2025 revenue of $83.0 million and delivered 26,841 total test reports. The company raised full‑year 2025 revenue guidance to $327–335 million from $310–320 million and launched AdvanceAD‑Tx, a 487‑gene expression test for systemic treatment decisions in moderate‑to‑severe atopic dermatitis (ages 12+).Core test volumes grew: DecisionDx‑Melanoma 10,459 and TissueCypher 10,609 reports in Q3; core revenue drivers test reports increased 36% year‑over‑year. The Novitas LCD excluding DecisionDx‑SCC (effective April 24, 2025) and discontinuation of IDgenetix affected revenue and volumes.

#CSTL Castle Biosciences Reports Third Quarter 2025 Results

www.stocktitan.net/news/CSTL/castle-bioscie...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis Castle Biosciences (Nasdaq: CSTL) launched AdvanceAD-Tx on November 3, 2025, a 487-gene expression profile test to guide systemic treatment choice for patients aged 12+ with moderate-to-severe atopic dermatitis.Validation data showed 30.4% of samples had a JAK inhibitor responder profile; those treated with JAKi reached EASI-90 by three months at 45.5% vs 8.3% (p=0.021), had higher vIGA-AD clear rates (36.4% vs 0%, p=0.006), more “no itch” reports (45.5% vs 8.3%, p=0.021), and remained flare-free more often (54.5% vs 16.7%, p=0.041).Castle estimates a U.S. TAM of $33 billion, is pursuing reimbursement pathways, and is beginning a measured limited-access commercial launch in November 2025 with phased expansion through 2026.

#CSTL Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

www.stocktitan.net/news/CSTL/castle-bioscie...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma Castle Biosciences (Nasdaq: CSTL) announced the publication of two significant studies validating their DecisionDx-SCC test for high-risk cutaneous squamous cell carcinoma (SCC). The first study demonstrated the test's ability to predict local recurrence in National Comprehensive Cancer Network (NCCN) high-risk patients post-Mohs surgery, adding to its existing capabilities of predicting metastasis risk and response to adjuvant radiation therapy (ART).The studies showed that DecisionDx-SCC significantly outperformed traditional staging systems, with three-year local recurrence-free survival rates of 95.3% (Class 1), 85.5% (Class 2A), and 71.4% (Class 2B). The test demonstrated superior predictive accuracy when combined with clinicopathologic factors, providing clinicians with actionable decision points for treatment planning.

#CSTL New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

www.stocktitan.net/news/CSTL/new-evidence-p...

0 0 0 0

Sesh

@seshsx.bsky.social

7 months ago

🀫 SONIC PLAYGROUND 2025 (Berlin) /// LIVE Ambient - Techno - Modular | Musikbrauerei | Tickets | SESH.sx Step into the immersive world of SONIC PLAYGROUND 2025, returning to the historic halls of Musikbrauerei in Berlin on November 22. The event brings together an

🀫 SONIC PLAYGROUND 2025 (Berlin) /// LIVE Ambient - Techno - Modular @ Musikbrauerei - 22 Nov feat. Miles Kvndra, cstl, Sholinger + more

#SESH #MilesKvndra #cstl #Sholinger

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

Castle (CSTL) Q2 Revenue Tops Estimates | The Motley Fool

#CSTL #26552025-323e-4e12-8479-c956d45eea9f #data-news

Origin | Interest | Match

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Castle Biosciences Reports Second Quarter 2025 Results Castle Biosciences (Nasdaq: CSTL) reported Q2 2025 financial results with revenue of $86.2 million. The company delivered 26,574 total test reports, a 6% increase year-over-year, with core tests DecisionDx-Melanoma and TissueCypher showing strong 33% combined growth.Key developments include FDA Breakthrough Device designation for DecisionDx-Melanoma, acquisition of Previse, and a collaboration with SciBase. The company raised its full-year 2025 revenue guidance to $310-320 million from $287-297 million. Q2 net income was $4.5 million with gross margin at 77%.Notable impacts include Novitas LCD affecting DecisionDx-SCC coverage and the discontinuation of IDgenetix in May 2025. The company maintained a strong financial position with $275.9 million in cash and investments as of June 30, 2025.

#CSTL Castle Biosciences Reports Second Quarter 2025 Results

www.stocktitan.net/news/CSTL/castle-bioscie...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

FDA Breakthrough: Castle Biosciences' New Melanoma Test Could Transform Cancer Diagnosis Revolutionary melanoma diagnostic test receives FDA Breakthrough designation, promising improved patient outcomes through personalized risk assessment. See clinical impact.

#CSTL FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test

www.stocktitan.net/news/CSTL/fda-grants-bre...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

Castle Biosciences Expands into Atopic Dermatitis Diagnostics with New SciBase Partnership Castle Biosciences (NASDAQ: CSTL) announced a new collaboration and license agreement with SciBase to co-develop diagnostic tools for dermatologic diseases, sta

#CSTL is expanding into atopic dermatitis diagnostics through a new partnership with SciBase. The goal: develop a test to predict AD flares before symptoms appear. Aimed at a U.S. patient base of up to 24M.
#CastleBiosciences
prismmarketview.com/castle-biosc...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

New Diagnostic Test Could Predict Atopic Dermatitis Flares Before Symptoms Appear Castle Biosciences targets 24M patient market with innovative diagnostic test for predicting atopic dermatitis flares. Learn about the groundbreaking SciBase partnership.

#CSTL Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

www.stocktitan.net/news/CSTL/castle-bioscie...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes Castle Biosciences (CSTL) will present new research at ASCO 2025 showcasing the effectiveness of their DecisionDx-Melanoma test in improving melanoma patient care. The study, involving over 13,500 patients, demonstrates that the test was associated with a 32% reduction in mortality risk compared to untested patients. The 31-gene expression profile test significantly stratified mortality risk within AJCC sub-stages, with Class 2B patients showing a hazard ratio of 4.59 and Class 1B/2A patients showing 3.42 (p91% sensitivity and 92% negative predictive value in distinguishing between low and high-risk uveal melanoma lesions through liquid biopsy.

#CSTL New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

www.stocktitan.net/news/CSTL/new-data-at-as...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Castle Biosciences Crushes Q1 Earnings: 21% Revenue Jump, Test Volume Soars 33%, Guidance Raised Castle Biosciences reports strong Q1 growth with $88M revenue, raises full-year outlook amid milestone achievement for melanoma testing. See complete results.

#CSTL Castle Biosciences Reports First Quarter 2025 Results

www.stocktitan.net/news/CSTL/castle-bioscie...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Castle Biosciences Acquires Johns Hopkins-Backed GI Health Company Previse to Transform Cancer Detection Castle Biosciences adds Johns Hopkins-developed methylation technology for GI cancer detection through Previse acquisition. See expansion details.

#CSTL Castle Biosciences to Acquire Previse

www.stocktitan.net/news/CSTL/castle-bioscie...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer Castle Biosciences (CSTL) will present new data on its TissueCypher Barrett's Esophagus test at the Digestive Disease Week (DDW 2025) Annual Meeting in San Diego from May 3-6. The company will showcase two key posters demonstrating TissueCypher's ability to identify patients with Barrett's esophagus who are at higher risk for developing esophageal cancer. A product theater featuring an expert physician panel will discuss clinical practice models for preventing progression from Barrett's to EAC. The presentations include research on the test's effectiveness in detecting missed neoplasia and providing risk stratification for Barrett's esophagus patients. Castle Biosciences will also participate in educational sessions in collaboration with GI experts and the American Society for Gastrointestinal Endoscopy (ASGE).

#CSTL New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

www.stocktitan.net/news/CSTL/new-data-at-dd...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity Castle Biosciences (Nasdaq: CSTL) has published a new study showing their DecisionDx-Melanoma test surpasses both AJCC staging and CP-GEP in identifying low-risk melanoma patients. The test achieved a 2.8% sentinel lymph node positivity rate, significantly below the NCCN guidelines' 5% threshold for avoiding sentinel lymph node biopsy (SLNB) surgery. The study, published in Cancer Diagnosis & Prognosis, analyzed T1-T2 melanoma tumors across multiple validation studies. While patients classified as low risk by CP-GEP showed a 6.2% SLN positivity rate, DecisionDx-Melanoma demonstrated superior performance at 2.8%. This improvement is particularly significant as over 90% of T1-T2 tumor patients who undergo SLNB receive negative results. The findings support using DecisionDx-Melanoma to guide SLNB decisions, especially for patients with thin tumors where surgical complications may outweigh benefits. The test provides personalized risk assessment for sentinel lymph node positivity and recurrence, enabling more informed melanoma management decisions.

#CSTL New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

www.stocktitan.net/news/CSTL/new-study-show...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Melanoma Diagnostic Breakthrough: DecisionDx Test Hits 200,000 Orders, Backed by 50+ Clinical Studies Revolutionary melanoma test achieves major adoption milestone, validated by 50+ peer-reviewed studies. See how this diagnostic tool is transforming cancer care outcomes.

#CSTL DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

www.stocktitan.net/news/CSTL/decision-dx-me...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

How Did Castle Biosciences Transform a $57.5M Loss Into $18.2M Profit? 2024 Results Reveal the Answer Castle Biosciences achieved 51% revenue growth to $332.1M with 36% test volume increase. Company turned $57.5M loss into $18.2M profit with strong cash position.

#CSTL Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results

www.stocktitan.net/news/CSTL/castle-bioscie...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Castle Biosciences Earnings Alert: Key Financial Results Coming Feb 27 - Here's How to Listen In Castle Biosciences schedules Q4 and FY2024 earnings call for February 27, featuring management presentation and investor Q&A. Access details for webcast and dial-in now available.

#CSTL Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025

www.stocktitan.net/news/CSTL/castle-bioscie...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Castle Biosciences' DecisionDx-SCC Shows 92% Accuracy in Groundbreaking 1,400-Patient Cancer Study Castle Biosciences' skin cancer test achieves breakthrough results in major study, demonstrating superior metastasis prediction and reducing unnecessary procedures by 25% in melanoma cases.

#CSTL Castle’s Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025

www.stocktitan.net/news/CSTL/castle-s-poste...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Castle Biosciences Expects 50% Revenue Growth in 2024, Hits Record 96,000 Tests Despite Medicare Setback Castle Biosciences projects $320-330M revenue for 2024, with test volume up 36% YoY. Strong growth in TissueCypher tests offsets Medicare non-coverage impact on DecisionDx-SCC.

#CSTL Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

www.stocktitan.net/news/CSTL/castle-bioscie...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Castle Biosciences' AI-Powered TissueCypher Test Gains Crucial NY State Approval for Cancer Detection Revolutionary AI-driven test for Barrett's Esophagus receives NY State approval, enabling early cancer risk detection for millions. Completes Castle's full portfolio approval.

#CSTL Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test

www.stocktitan.net/news/CSTL/castle-bioscie...

0 0 0 0